Table 1. Baseline characteristics of the 242 patients

Values are presented as median (interquartile range), number only, or number (%).

WBC, white blood cell count; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Table 2. The details of the initial endoscopic interventions

Values are presented as median (interquartile range) or number (%).

CI, confidence interval; EST, endoscopic sphincterotomy; EHL, electrohydraulic lithotripsy; CBD, common bile duct.

Table 3. Clinical success and adverse events of endoscopic procedures

Values are presented as number (%).

ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy.

Table 4. Risk factors for developing recurrent biliary obstruction after endoscopic interventions

HR, hazard ratio; CI, confidence interval; WBC, white blood cell count; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CBD, common bile duct; EST, endoscopic sphincterotomy; EHL, electrohydraulic lithotripsy; ERCP, endoscopic retrograde cholangiopancreatography.

Table 5. Baseline characteristics and the initial endoscopic interventions after propensity score matching

Values are presented as median (interquartile range), number only, or number (%).

WBC, white blood cell count; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CBD, common bile duct; EST, endoscopic sphincterotomy; EPLBD, endoscopic papillary large balloon dilation; POCS, peroral cholangioscopy; EHL, electrohydraulic lithotripsy.

Table 6. Baseline characteristics and the initial endoscopic interventions in indefinite stent maintenance group

Values are presented as median (interquartile range), number only, or number (%).

WBC, white blood cell count; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; EST, endoscopic sphincterotomy; EHL, electrohydraulic lithotripsy; CBD, common bile duct.